Journal article Open Access

Chromium Picolinate Intake and Risk of Type 2 Diabetes: An Evidence‐Based Review by the United States Food and Drug Administration

Trumbo PhD, Paula R.; Ellwood, Kathleen C.

The labeling of both health claims that meet significant scientific agreement (SSA) and qualified health claims on conventional foods and dietary supplements requires pre-market approval by the US Food and Drug Administration (FDA). Approval by the FDA involves, in part, a thorough review of the scientific evidence to support an SSA or a qualified health claim. This article discusses FDA's evidence-based review of the scientific evidence on the role of chromium picolinate supplements in reducing the risk of type 2 diabetes. Based on this evidence-based review, FDA issued a letter of enforcement discretion for one qualified health claim on chromium picolinate and risk of insulin resistance, a surrogate endpoint for type 2 diabetes. The agency concluded that the relationship between chromium picolinate intake and insulin resistance is highly uncertain.
Files (72.3 kB)
Name Size
article.pdf
md5:198f558d81ae89c3338a0533e40aaa42
72.3 kB Download
226
205
views
downloads
Views 226
Downloads 205
Data volume 14.8 MB
Unique views 224
Unique downloads 199

Share

Cite as